The data reported in Table 1 demonstrated that HER-3, though at different levels, is expressed homogeneously in a significant percentage (76%) of metastatic melanoma lesions tested, independently of their body location and sequence of appearance. Here, ERBB3 is linked to metastatic melanoma.